Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000088.xml
TumorDiagnostik & Therapie 2004; 25(4): 197
DOI: 10.1055/s-2004-813485
DOI: 10.1055/s-2004-813485
Symposium Report
© Georg Thieme Verlag KG Stuttgart · New York
Medikamentöse Therapie gastrointestinaler Stromatumoren bei Imatinib-Resistenz
Treatment Options for Imatinib-Resistant GISTFurther Information
Publication History
Publication Date:
23 August 2004 (online)
Schlüsselwörter
GIST - Imatinib-Resistenz - RAD001 - PKC412 - SU011248
Literatur
- 1 Huang S, Houghton P J. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003; 3 371-377
- 2 Maki R G. Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Curr Treat Options Gastroenterol. 2004; 7 13-17
- 3 Desai J, Maki R, Heinrich M C. et al . Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc ASCO. 2003; 22 Abstract 3273
- 4 Fabbro D, Ruetz S, Bodis S. et al . PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000; 15 17-28
Thomas Armbrust,
Giuliano Ramadori
Abteilung Gastroenterologie und Endokrinologie, Georg-August-Universität Göttingen
Robert-Koch-Straße 40
37099 Göttingen